drugset
drugset / Trial / NCT04082832

CuATSM Compared With Placebo for Treatment of ALS/MND

NCT04082832 ↗

Phase 2/3 Unknown 80 enrolled Collaborative Medicinal Development Pty Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or placebo for 6 x 28-day cycles (24 weeks) of treatment.

Timeline

Start
2019-09-30
Primary completion
2020-12-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator ATSM COPPER (II) Small molecule 72 mg Oral

Indications

amyotrophic lateral sclerosis